Last reviewed 2026-04-20 · How we verify

Initiating daily oral PrEP during pregnancy

University of North Carolina, Chapel Hill · FDA-approved active Small molecule Quality 2/100

Initiating daily oral PrEP during pregnancy is a Small molecule drug developed by University of North Carolina, Chapel Hill. It is currently FDA-approved. Also known as: Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC).

At a glance

Generic name	Initiating daily oral PrEP during pregnancy
Also known as	Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC)
Sponsor	University of North Carolina, Chapel Hill
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Initiating daily oral PrEP during pregnancy CI brief — competitive landscape report
Initiating daily oral PrEP during pregnancy updates RSS · CI watch RSS
University of North Carolina, Chapel Hill portfolio CI

Frequently asked questions about Initiating daily oral PrEP during pregnancy

What is Initiating daily oral PrEP during pregnancy?

Initiating daily oral PrEP during pregnancy is a Small molecule drug developed by University of North Carolina, Chapel Hill.

Who makes Initiating daily oral PrEP during pregnancy?

Initiating daily oral PrEP during pregnancy is developed and marketed by University of North Carolina, Chapel Hill (see full University of North Carolina, Chapel Hill pipeline at /company/university-of-north-carolina-chapel-hill).

Is Initiating daily oral PrEP during pregnancy also known as anything else?

Initiating daily oral PrEP during pregnancy is also known as Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC).

What development phase is Initiating daily oral PrEP during pregnancy in?

Initiating daily oral PrEP during pregnancy is FDA-approved (marketed).

Manufacturer: University of North Carolina, Chapel Hill — full pipeline
Also known as: Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC)
Compare: Initiating daily oral PrEP during pregnancy vs similar drugs
Pricing: Initiating daily oral PrEP during pregnancy cost, discount & access